A Copper Complex as Anti-Tumor Agents
</a><strong>Background</strong><br>
There is still a considerable demand for the improvement of cytotoxic cancer therapeutics regarding the toxicity and the tolerance. While platinum-based chemotherapy is the standard of care for patients with lung cancer, other metal-containing agents could not be established in the treatment of cancer diseases.<br><br> <strong>Technology</strong><br> Therefore, we offer a novel copper-based compound, displaying strong and selective anti-tumor activity in a broad range of hematological cancers and solid tumors, high efficiency against relapse, improved tolerance and reduced toxicity.<br><br> In vitro studies revealed strong apoptotic and anti-proliferative effects of metal- organic copper sarcolysin (MOC*Scr) in comparison to other cytotoxic drugs. When combined with other cytotoxic drugs, MOC*Scr showed strong synergistic effects pointing towards a different mechanism. Furthermore, MOC*Scr demonstrated potent activity in cell lines resistant to other standard drugs such as Vincristin, Daunorubicin and Doxorubicin. Additional in vivo studies revealed that the MOC*Src treatment leads to significant tumor growth reduction of 60-90% in syngenic and xenograft tumor models. Also terminal stage IV patients benefited from the treatment with MOC compound in investigator initiated trials.<br><br> Thus, these results position MOC*Scr as an exciting new cancer therapeutic agent.<br><br> <b>Benefits:</b><ul> <li>Excellent anti-tumor activity and synergistic effect with other cytotoxic drugs</li> <li>Wide spectrum of application including solid tumors and hematological cancers</li> <li>Overcomes resistances ex vivo</li> <li>Convenient oral administration</li> <li>Small molecule with short and simple synthesis</li></ul> <p><strong>IP Rights</strong><br> EP and PCT (DE, EP, AU, BR, CA, CN, IN, JP, RU, US) application filed in February 2008 and February 2009 <br><br> <strong>Patent Owner</strong><br> Technology Development Funds of Investitionsbank Berlin
Weitere Informationen: PDF
ipal GmbH
Tel.: +49 (0)30/2125-4820
Ansprechpartner
Dr. Dirk Dantz
Media Contact
Alle Nachrichten aus der Kategorie: Technologieangebote
Neueste Beiträge
Bakterien für klimaneutrale Chemikalien der Zukunft
Forschende an der ETH Zürich haben Bakterien im Labor so herangezüchtet, dass sie Methanol effizient verwerten können. Jetzt lässt sich der Stoffwechsel dieser Bakterien anzapfen, um wertvolle Produkte herzustellen, die…
Batterien: Heute die Materialien von morgen modellieren
Welche Faktoren bestimmen, wie schnell sich eine Batterie laden lässt? Dieser und weiteren Fragen gehen Forschende am Karlsruher Institut für Technologie (KIT) mit computergestützten Simulationen nach. Mikrostrukturmodelle tragen dazu bei,…
Porosität von Sedimentgestein mit Neutronen untersucht
Forschung am FRM II zu geologischen Lagerstätten. Dauerhafte unterirdische Lagerung von CO2 Poren so klein wie Bakterien Porenmessung mit Neutronen auf den Nanometer genau Ob Sedimentgesteine fossile Kohlenwasserstoffe speichern können…